pigofsteel. Apologies to those posters who don't like to compare...

pigofsteel.

Apologies to those posters who don't like to compare companies (put me on ignore). I don't hold AVH although I did have a look at them (along with TIS) when I was looking for biotechs for my portfolio. I like both companies but thought there was more potential upside to TIS.

Both companies have a similar net asset position (TIS $17m and AVH $16m) but there is a very lage difference in their contributed capital and accumulated losses.

Things I like about AVH are that they have a steady and growing revenue stream in place and the way they are consistently reducing their annual losses. I also like the fact that Prof Fiona Wood is a non-executive director on AVH - she is very highly regarded for her work with burns patients and the Bali bombing victims.

IMO health practitioners are a pretty conservative group with new products and have a strong focus on costs. I think this trait won't harm TIS as there have been quite outstanding trial results and the product is very cost effective. DYOR but I have also read in other forums that Australian medicos are quite keen for the product to be released in Australia. (sorry Bumskins I don't have a link to that information).